Gouty arthritis is a type of inflammatory arthritis that is mediated by the deposition of monosodium urate crystals and is an important burden on healthcare worldwide. The aim of this comprehensive review is to discuss the most recent advances regarding the mechanisms of treatment for gout, from classic pharmacological interventions to emerging therapeutic strategies. The chapter dissects the pathophysiology of gout through hyperuricemia, crystal deposition, and inflammatory responses to form a basis for the discussion of current treatment approaches; pharmacological interventions are described-side by side with lifestyle modifications-including NSAIDs, colchicine, and xanthine oxidase inhibitors. Newer approaches to management are discussed, including the use of biologics targeting IL-1beta, newer agents in development, and personalized medicine. It also outlines the future directions in gout research, focusing on the development of novel imaging techniques, biomarkers for treatment response, and targeting novel pathways. This review serves as an overall guide for clinicians and researchers and all other stakeholders interested in further advancing the specialty of gouty arthritis. Key words Gouty arthritis " Serum urate " Hyperuricemia " Crystal deposition " Colchicine.

Department of Rheumatology 1st Affiliated Hospital Heilongjiang University of Chinese Medicine Harbin China or

Zobrazit více v PubMed

Galozzi P, Bindoli S, Doria A, Oliviero F, Sfriso P. Autoinflammatory features in gouty arthritis. J Clin Med. 2021;10:1880. doi: 10.3390/jcm10091880. PubMed DOI PMC

Keller SF, Mandell BF. Management and cure of gouty arthritis. Med Clin North Am. 2021;105:297–310. doi: 10.1016/j.mcna.2020.09.013. PubMed DOI

Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020;16:380–390. doi: 10.1038/s41584-020-0441-1. PubMed DOI

Asghari KM, Zahmatyar M, Seyedi F, Motamedi A, Zolfi M, Alamdary SJ, Fazlollahi A, Shamekh A, Mousavi SE, Nejadghaderi SA. Gout: global epidemiology, risk factors, comorbidities and complications: a narrative review. BMC Musculoskelet Disord. 2024;25:1047. doi: 10.1186/s12891-024-08180-9. PubMed DOI PMC

Patil T, Soni A, Acharya S. A brief review on in vivo models for gouty arthritis. Metabol Open. 2021;11:100100. doi: 10.1016/j.metop.2021.100100. PubMed DOI PMC

Wilson L, Saseen JJ. Gouty arthritis: a review of acute management and prevention. Pharmacotherapy. 2016;36:906–922. doi: 10.1002/phar.1788. PubMed DOI

Du L, Zong Y, Li H, Wang Q, Xie L, Yang B, Pang Y, Zhang C, Zhong Z, Gao J. Hyperuricemia and its related diseases: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9:212. doi: 10.1038/s41392-024-01916-y. PubMed DOI PMC

AlJadir S. Case report and disease review: Tophaceous gouty arthropathy. Endocrinol Metab Int J. 2022;9:72–80. doi: 10.15406/emij.2022.10.00312. DOI

Zhang Y, Chen S, Yuan M, Xu Y, Xu H. Gout and diet: a comprehensive review of mechanisms and management. Nutrients. 2022;14:3525. doi: 10.3390/nu14173525. PubMed DOI PMC

Dalbeth N, Choi HK, Joosten LAB, Khanna PP, Matsuo H, Perez-Ruiz F, Stamp LK. Gout. Nat Rev Dis Primers. 2019;5:69. doi: 10.1038/s41572-019-0115-y. PubMed DOI

Nian Y-L, You C-G. Susceptibility genes of hyperuricemia and gout. Hereditas. 2022;159:30. doi: 10.1186/s41065-022-00243-y. PubMed DOI PMC

Ichida K, Matsuo H, Takada T, Nakayama A, Murakami K, Shimizu T, Yamanashi Y, et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun. 2012;3:764. doi: 10.1038/ncomms1756. PubMed DOI PMC

Chen C, Wang J, Liang Z, Li M, Fu D, Zhang L, Yang X, Guo Y, Ge D, Liu Y. Monosodium urate crystals with controlled shape and aspect ratio for elucidating the pathological progress of acute gout. Biomater Adv. 2022;139:213005. doi: 10.1016/j.bioadv.2022.213005. PubMed DOI

Galozzi P, Bindoli S, Luisetto R, Sfriso P, Ramonda R, Scanu A, Oliviero F. Regulation of crystal induced inflammation: current understandings and clinical implications. Expert Rev Clin Immunol. 2021;17:773–787. doi: 10.1080/1744666X.2021.1937129. PubMed DOI

Cha Y, Lee J, Choy W, Lee JS, Lee HH, Chae D-S. Pathophysiology and treatment of gout arthritis; including gout arthritis of hip joint: a literature review. Hip Pelvis. 2024;36:1. doi: 10.5371/hp.2024.36.1.1. PubMed DOI PMC

Laurent MR. Bone and joint disorders. In: Wasserman MR, Bakerjian D, Linnebur S, Brangman S, Cesari M, Rosen S, editors. Geriatric Medicine: A Person Centered Evidence Based Approach. Springer Nature; 2024. pp. 721–760. DOI

Vandendriessche S, Cambier S, Proost P, Marques PE. Complement receptors and their role in leukocyte recruitment and phagocytosis. Front Cell Dev Biol. 2021;9:624025. doi: 10.3389/fcell.2021.624025. PubMed DOI PMC

Silva LB, dos Santos Neto AP, Maia SMAS, dos Santos Guimarães C, Quidute IL, Carvalho AdAT, Severino A, et al. The role of TNF-α as a proinflammatory cytokine in pathological processes. Open Dent J. 2019;13:332–338. doi: 10.2174/1874210601913010332. DOI

Kaur H, Ghorai SM. Role of cytokines as immunomodulators. In: Kesharwani RK, Keservani RK, Sharma AK, editors. Immunomodulators and Human Health. Springer Nature; 2022. pp. 371–414. DOI

Proudman C, Lester SE, Gonzalez-Chica DA, Gill TK, Dalbeth N, Hill CL. Gout, flares, and allopurinol use: a population-based study. Arthritis Res Ther. 2019;21:1–8. doi: 10.1186/s13075-019-1918-7. PubMed DOI PMC

Ekpenyong CE, Daniel N. Roles of diets and dietary factors in the pathogenesis, management and prevention of abnormal serum uric acid levels. PharmaNutrition. 2015;3:29–45. doi: 10.1016/j.phanu.2014.12.001. DOI

Spragg JC, Michael TJ, Aslani P, Coleshill MJ, Chan JS, Day RO, Stocker SL. Optimizing adherence to allopurinol for gout: patients’ perspectives. Br J Clin Pharmacol. 2023;89:1978–1991. doi: 10.1111/bcp.15657. PubMed DOI

Soskind R, Abazia DT, Bridgeman MB. Updates on the treatment of gout, including a review of updated treatment guidelines and use of small molecule therapies for difficult-to-treat gout and gout flares. Expert Opin Pharmacother. 2017;18:1115–1125. doi: 10.1080/14656566.2017.1349099. PubMed DOI

Atkinson TJ, Fudin J. Nonsteroidal antiinflammatory drugs for acute and chronic pain. Phys Med Rehabil Clin N Am. 2020;31:219–231. doi: 10.1016/j.pmr.2020.01.002. PubMed DOI

Gracheva IA, Shchegravina ES, Schmalz H-G, Beletskaya IP, Fedorov AY. Colchicine alkaloids and synthetic analogues: current progress and perspectives. J Med Chem. 2020;63:10618–10651. doi: 10.1021/acs.jmedchem.0c00222. PubMed DOI

Stone S, Malanga GA, Capella T. Corticosteroids: review of the history, the effectiveness, and adverse effects in the treatment of joint pain. Pain Physician. 2021;24(S1):S233–S246. doi: 10.36076/ppj.2021.24.S233-S246. PubMed DOI

Alghamdi AA, Althumali JS, Almalki MMM, Almasoudi AS, Almuntashiri AH, Almuntashiri AH, Mohammed AI, et al. An overview on the role of xanthine oxidase inhibitors in gout management. Arch Pharm Pract. 2021;12:94–99. doi: 10.51847/RkCPaycprc. DOI

Jenkins C, Hwang JH, Kopp JB, Winkler CA, Cho SK. Review of urate-lowering therapeutics: From the past to the future. Front Pharmacol. 2022;13:925219. doi: 10.3389/fphar.2022.925219. PubMed DOI PMC

Nielsen SM, Zobbe K, Kristensen LE, Christensen R. Nutritional recommendations for gout: An update from clinical epidemiology. Autoimmun Rev. 2018;17:1090–1096. doi: 10.1016/j.autrev.2018.05.008. PubMed DOI

Rai SK, Fung TT, Lu N, Keller SF, Curhan GC, Choi HK. The Dietary Approaches to Stop Hypertension (DASH) diet, Western diet, and risk of gout in men: prospective cohort study. BMJ. 2017;357:j1794. doi: 10.1136/bmj.j1794. PubMed DOI PMC

Yokose C, McCormick N, Lu N, Joshi AD, Curhan G, Choi HK. Adherence to 2020 to 2025 Dietary Guidelines for Americans and the risk of new-onset female gout. JAMA Intern Med. 2022;182:254–264. doi: 10.1001/jamainternmed.2021.7419. PubMed DOI PMC

Dessein PH, Shipton EA, Stanwix AE, Joffe BI, Ramokgadi J. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis. 2000;59:539–543. doi: 10.1136/ard.59.7.539. PubMed DOI PMC

Kakutani-Hatayama M, Kadoya M, Okazaki H, Kurajoh M, Shoji T, Koyama H, Tsutsumi Z, et al. Nonpharmacological management of gout and hyperuricemia: hints for better lifestyle. Am J Lifestyle Med. 2017;11:321–329. doi: 10.1177/1559827615601973. PubMed DOI PMC

Ma W, Ye G, Liu Y, Sun W, Huang X, Hu L, Chen L, Huang B, Li H. Impact of alcohol consumption on hyperuricemia and gout: a systematic review and meta-analysis. Front Nutr. 2025;12:1588980. doi: 10.3389/fnut.2025.1588980. PubMed DOI PMC

Saag KG, Khanna PP, Keenan RT, Ohlman S, Osterling Koskinen L, Sparve E, Åkerblad AC, Wikén M, So A, Pillinger MH. A randomized, phase II study evaluating the efficacy and safety of anakinra in the treatment of gout flares. Arthritis Rheumatol. 2021;73:1533–1542. doi: 10.1002/art.41699. PubMed DOI

Jena M, Tripathy A, Mishra A, Maiti R. Effect of canakinumab on clinical and biochemical parameters in acute gouty arthritis: a meta-analysis. Inflammopharmacology. 2021;29:35–47. doi: 10.1007/s10787-020-00753-z. PubMed DOI

Maher D, Reeve E, Hopkins A, Tan JM, Tantiongco M, Ailabouni N, Woodman R, et al. Comparative risk of gout flares when initiating or escalating various urate-lowering therapy: a systematic review with network meta-analysis. Arthritis Care Res (Hoboken) 2024;76:871–881. doi: 10.1002/acr.25309. PubMed DOI

Botson J, Obermeyer K, LaMoreaux B, Padnick-Silver L, Verma S, Weinblatt ME, Peterson J. Quality of life and clinical gout assessments during pegloticase with and without methotrexate co-therapy: MIRROR randomized controlled trial exploratory findings. Rheumatol Adv Pract. 2024;8:rkae145. doi: 10.1093/rap/rkae145. PubMed DOI PMC

Yang S, Hu Q, Liu K, Xiao B, Zhang B, Su N. Serum uric acid reduction through SGLT2 inhibitors: evidence from a systematic review and meta-analysis. Front Pharmacol. 2025;16:1551390. doi: 10.3389/fphar.2025.1551390. PubMed DOI PMC

Tesfaye H, Wang KM, Zabotka LE, Wexler DJ, Schmedt N, Koeneman L, Seman L, et al. Empagliflozin and risk of incident gout: analysis from the EMPagliflozin Comparative Effectiveness and SafEty (EMPRISE) Cohort Study. J Gen Intern Med. 2024;39:1870–1879. doi: 10.1007/s11606-024-08793-9. PubMed DOI PMC

Zhou J, Zhang Y, Cheng L. Meta-analysis of the effect of losartan relative to other angiotensin receptor antagonists on serum uric acid level. Trop J Pharm Res. 2023;22:1999–2008. doi: 10.4314/tjpr.v22i9.31. DOI

Jiao X-F, Song K, Jiao X, Li H, Zeng L, Zou K, Zhang W, Wang H, Zhang L. Hyperuricaemia, gout and related adverse events associated with antihypertensive drugs: a real-world analysis using the FDA adverse event reporting system. Front Pharmacol. 2023;13:1045561. doi: 10.3389/fphar.2022.1045561. PubMed DOI PMC

Kaufmann D, Chaiyakunapruk N, Schlesinger N. Optimizing gout treatment: a comprehensive review of current and emerging uricosurics. Joint Bone Spine. 2025;92:105826. doi: 10.1016/j.jbspin.2024.105826. PubMed DOI

Zairol Azwan FA, Teo YY, Mohd Tahir NA, Saffian SM, Makmor-Bakry M, Mohamed Said MS. A systematic review of single nucleotide polymorphisms affecting allopurinol pharmacokinetics and serum uric acid level. Pharmacogenomics. 2024;25:479–494. doi: 10.1080/14622416.2024.2403969. PubMed DOI PMC

Terkeltaub R, Lee J, Min J, Shin S, Saag KG. Serum urate-lowering efficacy and safety of tigulixostat in gout patients with hyperuricemia: a randomized, double-blind, placebo-controlled, dose-finding trial. Arthritis Rheumatol. 2023;75:1275–1284. doi: 10.1002/art.42447. PubMed DOI

Saag KG, Dalbeth N, Hsu CY, Kuo CF, Nuki G, Perez-Ruiz F, White WB, et al. Evaluation of the efficacy and safety of a novel xanthine oxidase inhibitor, tigulixostat, in gout patients with hyperuricemia: design of the EURELIA 1 and EURELIA 2 studies. Contemp Clin Trials. 2025;151:107843. doi: 10.1016/j.cct.2025.107843. PubMed DOI

Hsu TM, Chang HW, Chen AL, Wei JC. Comment on serum urate-lowering efficacy and safety of tigulixostat in gout patients with hyperuricemia: a randomized, double-blind, placebo-controlled, dose-finding trial. Int J Rheum Dis. 2024;27:e15024. doi: 10.1111/1756-185X.15024. PubMed DOI

Liu N, Xu H, Sun Q, Yu X, Chen W, Wei H, Jiang J, Xu Y, Lu W. The role of oxidative stress in hyperuricemia and xanthine oxidoreductase (XOR) inhibitors. Oxid Med Cell Longev. 2021;2021:1470380. doi: 10.1155/2021/1470380. PubMed DOI PMC

Stockert AL, Stechschulte M. Allopurinol to febuxostat: how far have we come? Clin Med Insights Ther. 2010;2:CMT.S6286. doi: 10.4137/CMT.S6286. DOI

Miner JN, Tan PK, Hyndman D, Liu S, Iverson C, Nanavati P, Hagerty DT, Manhard K, Shen Z, Girardet J-L. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Res Ther. 2016;18:1–10. doi: 10.1186/s13075-016-1150-7. PubMed DOI PMC

Wolff ML, Cruz JL, Vanderman AJ, Brown JN. The effect of angiotensin II receptor blockers on hyperuricemia. Ther Adv Chronic Dis. 2015;6:339–346. doi: 10.1177/2040622315596119. PubMed DOI PMC

Kumar N, Husain S, Haque ZU, Aleem A, Rizwan F, Bhatti MI. The effects of beta blocker (metoprolol) & calcium channel blockers (amlodipine) on serum uric acid levels in the patients of hypertension. Pak J Med Health Sci. 2022;16:597–599. doi: 10.53350/pjmhs22165597. DOI

Szekanecz Z, Szamosi S, Kovács GE, Kocsis E, Benkő S. The NLRP3 inflammasome-interleukin 1 pathway as a therapeutic target in gout. Arch Biochem Biophys. 2019;670:82–93. doi: 10.1016/j.abb.2019.01.031. PubMed DOI

Schlesinger N. Anti-interleukin-1 therapy in the management of gout. Curr Rheumatol Rep. 2014;16:1–6. doi: 10.1007/s11926-013-0398-z. PubMed DOI

So A, De Meulemeester M, Pikhlak A, Yücel AE, Richard D, Murphy V, Arulmani U, Sallstig P, Schlesinger N. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum. 2010;62:3064–3076. doi: 10.1002/art.27600. PubMed DOI

Jeria-Navarro S, Gomez-Gomez A, Park HS, Calvo-Aranda E, Corominas H, Pou MA, Diaz-Torne C. Effectiveness and safety of anakinra in gouty arthritis: a case series and review of the literature. Front Med (Lausanne) 2022;9:1089993. doi: 10.3389/fmed.2022.1089993. PubMed DOI PMC

James R, Paul BJ. New and emerging therapies in gout. Rheumatol Autoimmun. 2023;3:70–77. doi: 10.1002/rai2.12064. DOI

Pascart T, Richette P. Investigational drugs for hyperuricemia, an update on recent developments. Expert Opin Investig Drugs. 2018;27:437–444. doi: 10.1080/13543784.2018.1471133. PubMed DOI

Zeng L, Deng Y, He Q, Yang K, Li J, Xiang W, Liu H, Zhu X, Chen H. Safety and efficacy of probiotic supplementation in 8 types of inflammatory arthritis: a systematic review and meta-analysis of 34 randomized controlled trials. Front Immunol. 2022;13:961325. doi: 10.3389/fimmu.2022.961325. PubMed DOI PMC

Han Y, Yao M, Zhao H, Han X, Di H, Xie T, Wu J, Wang Y, Zhang Y, Zeng X. Exploration of the interrelationship between serum uric acid, gout, and cardiac, renal, and metabolic conditions in middle-aged and older people. J Am Heart Assoc. 2025;14:e038723. doi: 10.1161/JAHA.124.038723. PubMed DOI PMC

Nieradko-Iwanicka B. What is the role of angiotensin receptor blockers in treatment of hyperuricemia coexisting with arterial hypertension? Reumatologia (Rheumatol) 2018;56:106–110. doi: 10.5114/reum.2018.75522. PubMed DOI PMC

Banerjee M, Pal R, Mukhopadhyay S. Can SGLT2 inhibitors prevent incident gout? A systematic review and meta-analysis. Acta Diabetol. 2022;59:783–791. doi: 10.1007/s00592-022-01866-3. PubMed DOI

Wu R, Cheng YJ, Zhu LL, Yu L, Zhao XK, Jia M, Wen CH, et al. Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies. Oncotarget. 2016;7:81870–81879. doi: 10.18632/oncotarget.13250. PubMed DOI PMC

Ferngprayoon P, Sukasem C, Palapinyo S, Taibanguay N, Puttilerpong C. The outcome of HLA-B*58:01 screening test before initiating allopurinol at a tertiary hospital. Thai J Pharm Sci. 2024;48:1. doi: 10.56808/3027-7922.2967. DOI

Terashima R, Medina AJP, Del Mundo HJF, Briones RSS, Aquino JAB, Quiminiano EM, Sin YM, et al. Prevalence of Human Leukocyte Antigen (HLA)-B*58:01 and allopurinol-induced adverse reactions in Filipino patients in Hawai’i: implications for genotyping. Int J Rheum Dis. 2025;28:e70127. doi: 10.1111/1756-185X.70127. PubMed DOI

Stitt R, Pinto B, June R. AB1615-HPR HLAB5801 testing for patients at high risk for allopurinol hypersensitivity syndrome: a quality improvement initiative. Ann Rheum Dis. 2024;83:2182–2183. doi: 10.1136/annrheumdis-2024-eular.2403. DOI

Pavelcova K, Bohata J, Pavlikova M, Bubenikova E, Pavelka K, Stiburkova B. Evaluation of the influence of genetic variants of SLC2A9 (GLUT9) and SLC22A12 (URAT1) on the development of hyperuricemia and gout. J Clin Med. 2020;9:2510. doi: 10.3390/jcm9082510. PubMed DOI PMC

Cleophas M, Joosten L, Stamp LK, Dalbeth N, Woodward OM, Merriman TR. ABCG2 polymorphisms in gout: insights into disease susceptibility and treatment approaches. Pharmacogenomics Pers Med. 2017;10:129–142. doi: 10.2147/PGPM.S105854. PubMed DOI PMC

Alrajeh KY, Roman YM. Pharmacogenetic perspective for optimal gout management. Future Pharmacol. 2022;2:135–152. doi: 10.3390/futurepharmacol2020011. DOI

Pillinger MH, Mandell BF. Therapeutic approaches in the treatment of gout. Semin Arthritis Rheum. 2020;50(3S):S24–S30. doi: 10.1016/j.semarthrit.2020.04.010. PubMed DOI

Lin Z, Gupta JK, Maqbool M, Kumar K, Sharma A, Wahi N. The therapeutic management of chemical and herbal medications on uric acid levels and gout: modern and traditional wisdom. Pharmaceuticals (Basel) 2024;17:1507. doi: 10.3390/ph17111507. PubMed DOI PMC

Terkeltaub R. Emerging urate-lowering drugs and pharmacologic treatment strategies for gout: a narrative review. Drugs. 2023;83:1501–1521. doi: 10.1007/s40265-023-01944-y. PubMed DOI

Artasensi A, Pedretti A, Vistoli G, Fumagalli L. Type 2 diabetes mellitus: a review of multi-target drugs. Molecules. 2020;25:1987. doi: 10.3390/molecules25081987. PubMed DOI PMC

Terkeltaub R, Dodd D. The Gut Microbiome in Hyperuricemia and Gout. Arthritis Rheumatol. 2025;77:955–965. doi: 10.1002/art.43118. PubMed DOI PMC

Kiltz U, Smolen J, Bardin T, Solal AC, Dalbeth N, Doherty M, Engel B, Flader C, Kay J, Matsuoka M. Treat-to-target (T2T) recommendations for gout. Ann Rheum Dis. 2017;76:632–638. doi: 10.1136/annrheumdis-2016-209467. PubMed DOI

Uhlig T, Karoliussen LF, Sexton J, Borgen T, Haavardsholm EA, Kvien TK, Hammer HB. 12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: achievements of the urate target levels and predictors of obtaining this target. RMD Open. 2021;7:e001628. doi: 10.1136/rmdopen-2021-001628. PubMed DOI PMC

Solomon DH, Paudel M, Chitineni S, Fernandes A, Pham T, Billa S, Yokose C, et al. The design of a randomized controlled active-comparator strategy trial for gout: treat to target serum urate versus treat to avoid symptoms. ACR Open Rheumatol. 2025;7:e70012. doi: 10.1002/acr2.70012. PubMed DOI PMC

Yang AY. Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases. Int J Clin Pharmacol Ther. 2020;58:21. doi: 10.5414/CP203466. PubMed DOI

Baraf HS, Yood RA, Ottery FD, Sundy JS, Becker MA. Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy. J Clin Rheumatol. 2014;20:427–432. doi: 10.1097/RHU.0000000000000200. PubMed DOI PMC

Cicero AF, Fogacci F, Cincione RI, Tocci G, Borghi C. Clinical effects of xanthine oxidase inhibitors in hyperuricemic patients. Med Princ Pract. 2021;30:122–130. doi: 10.1159/000512178. PubMed DOI PMC

Chen SK, Liu J, Kim SC. Real-world patterns of pegloticase use for treatment of gout: descriptive multidatabase cohort study. BMJ Open. 2020;10:e041167. doi: 10.1136/bmjopen-2020-041167. PubMed DOI PMC

Howren A, Tsao NW, Choi HK, Shojania K, Kydd A, Friesen R, Avina-Zubieta JA, De Vera MA. eHealth-supported decentralized multi-disciplinary care for gout involving rheumatology, pharmacy, and dietetics: proof-of-concept study. Clin Rheumatol. 2020;39:1241–1249. doi: 10.1007/s10067-019-04809-6. PubMed DOI

Tsiamalou P, Brotis AG, Vrekou E, Georgakopoulou VE, Papalexis P, Aravanatinou-Fatorou A, Tegousi M, Fotakopoulos G, Paterakis K. The nurse’s role in managing gout in the modern era: a systematic review of the literature. Medicine (Baltimore) 2023;3:40. doi: 10.3892/mi.2023.100. PubMed DOI PMC

Doherty M, Jenkins W, Richardson H, Sarmanova A, Abhishek A, Ashton D, Barclay C, et al. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomized controlled trial. Lancet. 2018;392:1403–1412. doi: 10.1016/S0140-6736(18)32158-5. PubMed DOI PMC

Yao TK, Lee RP, Wu WT, Chen IH, Yu TC, Yeh KT. Advances in Gouty Arthritis Management: Integration of Established Therapies, Emerging Treatments, and Lifestyle Interventions. Int J Mol Sci. 2024;25:10853. doi: 10.3390/ijms251910853. PubMed DOI PMC

Mikuls TR, Cheetham TC, Levy GD, Rashid N, Kerimian A, Low KJ, Coburn BW, et al. Adherence and outcomes with urate-lowering therapy: a site-randomized trial. Am J Med. 2019;132:354–361. doi: 10.1016/j.amjmed.2018.11.011. PubMed DOI PMC

Day RO, Graham GG. Non-steroidal anti-inflammatory drugs (NSAIDs) BMJ. 2013;346:f3195. doi: 10.1007/978-3-0348-0620-6_52-2. PubMed DOI

Kapugi M, Cunningham K. Corticosteroids. Orthop Nurs. 2019;38:336–339. doi: 10.1097/NOR.0000000000000595. PubMed DOI

Perez-Ruiz F, Desideri G. Improving adherence to gout therapy: an expert review. Ther Clin Risk Manag. 2018:793–802. doi: 10.2147/TCRM.S162956. PubMed DOI PMC

Spragg JC, Michael TJ, Aslani P, Coleshill MJ, Chan JS, Day RO, Stocker SL. Optimizing adherence to allopurinol for gout: patients’ perspectives. Br J Clin Pharmacol. 2023;89:1978–1991. doi: 10.1111/bcp.15657. PubMed DOI

Rai SK, Choi HK, Choi SH, Townsend AF, Shojania K, De Vera MA. Key barriers to gout care: a systematic review and thematic synthesis of qualitative studies. Rheumatology (Oxford) 2018;57:1282–1292. doi: 10.1093/rheumatology/kex530. PubMed DOI PMC

Michael TJ, Wright DF, Chan JS, Coleshill MJ, Aslani P, Hughes DA, Day RO, Stocker SL. Patient-led urate self-monitoring to improve clinical outcomes in people with gout: a feasibility study. ACR Open Rheumatol. 2024;6:403–411. doi: 10.1002/acr2.11666. PubMed DOI PMC

Robinson PC. Gout-an update of aetiology, genetics, co-morbidities and management. Maturitas. 2018;118:67–73. doi: 10.1016/j.maturitas.2018.10.012. PubMed DOI

Guthridge JM, Wagner CA, James JA. The promise of precision medicine in rheumatology. Nat Med. 2022;28:1363–1371. doi: 10.1038/s41591-022-01880-6. PubMed DOI PMC

Galić I, Habijan M, Leventić H, Romić K. Machine learning empowering personalized medicine: a comprehensive review of medical image analysis methods. Electronics. 2023;12:4411. doi: 10.3390/electronics12214411. DOI

Eroğul Ö, Ertürk A, Doğan M, Kurt K, Kaşıkcı M. Evaluation of macular and optic disc radial peripapillary vessel density using optical coherence tomography angiography in gout patients. Diagnostics (Basel) 2023;13:3651. doi: 10.3390/diagnostics13243651. PubMed DOI PMC

Xie J, He C, Su Y, Ding Y, Zhu X, Xu Y, Ding J, Zhou H, Wang H. Research progress on microRNA in gout. Front Pharmacol. 2022;13:981799. doi: 10.3389/fphar.2022.981799. PubMed DOI PMC

Barshop BA, Nyhan WL. Purines and pyrimidines. In: Rosenberg RN, Pascual JM, editors. Rosenberg’s Molecular and Genetic Basis of Neurological and Psychiatric Disease. Academic Press; 2025. pp. 897–916. DOI

Yang Q, Su L, Zhao L. Research progress of drugs for the treatment of gout. Int J Biol Life Sci. 2023;4:40–42. doi: 10.54097/ijbls.v4i3.11. DOI

Nag S, Mohanto S, Ahmed MG, Subramaniyan V. “Smart” stimuli-responsive biomaterials revolutionizing the theranostic landscape of inflammatory arthritis. Mater Today Chem. 2024;39:102178. doi: 10.1016/j.mtchem.2024.102178. DOI

Coppola C, Greco M, Munir A, Musarò D, Quarta S, Massaro M, Lionetto MG, Maffia M. Osteoarthritis: insights into diagnosis, pathophysiology, therapeutic avenues, and the potential of natural extracts. Curr Issues Mol Biol. 2024;46:4063–4105. doi: 10.3390/cimb46050251. PubMed DOI PMC

Bland JS. Therapeutic use of omega-3 fatty acids for immune disorders in search of the ideal omega-3 supplement. Integr Med (Encinitas) 2022;21:14–18. PubMed PMC

Jaén RI, Sánchez-García S, Fernández-Velasco M, Boscá L, Prieto P. Resolution-based therapies: the potential of lipoxins to treat human diseases. Front Immunol. 2021;12:658840. doi: 10.3389/fimmu.2021.658840. PubMed DOI PMC

Memarzia A, Khazdair MR, Behrouz S, Gholamnezhad Z, Jafarnezhad M, Saadat S, Boskabady MH. Experimental and clinical reports on anti-inflammatory, antioxidant, and immunomodulatory effects of Curcuma longa and curcumin, an updated and comprehensive review. BioFactors. 2021;47:311–350. doi: 10.1002/biof.1716. PubMed DOI

Imperador CHL, Scarim CB, Bosquesi PL, Lopes JR, Cardinalli Neto A, Giarolla J, Ferreira EI, Dos Santos JL, Chin CM. Resveratrol and curcumin for Chagas disease treatment-a systematic review. Pharmaceuticals (Basel) 2022;15:609. doi: 10.3390/ph15050609. PubMed DOI PMC

Romano A, Mortellaro A. The new frontiers of gene therapy and gene editing in inflammatory diseases. Hum Gene Ther. 2024;35:219–231. doi: 10.1089/hum.2023.210. PubMed DOI

Sisodiya SM. Precision medicine and therapies of the future. Epilepsia. 2021;62(Suppl 2):S90–S105. doi: 10.1111/epi.16539. PubMed DOI PMC

He H, Cheng Q, Chen S, Li Q, Zhang J, Shan G, Zhang M. Triglyceride-glucose index and its additive interaction with ABCG2/SLC2A9 polygenic risk score on hyperuricemia in middle age and older adults: findings from the DLCC and BHMC study. Ann Med. 2024;56:2434186. doi: 10.1080/07853890.2024.2434186. PubMed DOI PMC

Roman YM. Moving the needle in gout management: the role of culture, diet, genetics, and personalized patient care practices. Nutrients. 2022;14:3590. doi: 10.3390/nu14173590. PubMed DOI PMC